Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-09

AUTHORS

Osvaldo Ulises Garay, Marie Libérée Nishimwe, Marwân-Al-Qays Bousmah, Asmaa Janah, Pierre-Marie Girard, Geneviève Chêne, Laetitia Moinot, Luis Sagaon-Teyssier, Jean-Luc Meynard, Bruno Spire, Sylvie Boyer

ABSTRACT

BACKGROUND: Protease inhibitor monotherapy is a simplified treatment strategy for virally suppressed HIV-positive patients that has the potential for cost savings, as fewer drugs are used than with combination therapy. However, evidence for its economic value is limited. OBJECTIVES: We assessed the cost-effectiveness of lopinavir/ritonavir monotherapy followed by treatment intensification in case of viral load rebound versus combination antiretroviral therapy (cART) with efavirenz/emtricitabine/tenofovir in HIV-1 infected patients with viral suppression in the ANRS 140 DREAM trial. METHODS: DREAM was conducted in 36 French Hospitals between 2009 and 2013. For each treatment strategy, we estimated the unadjusted and multivariate-adjusted mean costs (in €, year 2010 values) and quality-adjusted life-years (QALYs) per patient, as well as incremental costs and QALYs per patient. We then assessed uncertainty using the cost-effectiveness acceptability curve, scenario analyses and cost-effectiveness price-threshold (CEPT) analysis. RESULTS: In the base-case analysis considering 2009-2013 antiretroviral drug (ARV) prices, adjusted incremental costs and QALYs were - €3296 (95% confidence interval [CI] - 5202 to - 1391) and 0.006 (95% CI - 0.021 to 0.033), respectively, over 2 years, suggesting that monotherapy was cost-effective with a probability of 100% at various cost-effectiveness thresholds. In scenario analyses considering 2018 ARV prices, monotherapy remained cost-effective but with a lower probability (94% vs. 100% in the base-case analysis). The current price of cART would have to decrease by 34% to be cost-effective with a probability of 95%. CONCLUSION: Monotherapy appears to be cost-effective compared with cART for virologically suppressed HIV-positive patients in France. CEPT analysis is a useful tool to identify the preferred strategy to adopt given that ARV prices change rapidly. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT00946595. More... »

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s41669-019-0130-7

DOI

http://dx.doi.org/10.1007/s41669-019-0130-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113328131

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30968368


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Economic & Social Sciences, Health Systems & Medical Informatics", 
          "id": "https://www.grid.ac/institutes/grid.464064.4", 
          "name": [
            "INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de La Sant\u00e9 & Traitement de l'Information M\u00e9dicale, Aix Marseille University, Marseille, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garay", 
        "givenName": "Osvaldo Ulises", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Economic & Social Sciences, Health Systems & Medical Informatics", 
          "id": "https://www.grid.ac/institutes/grid.464064.4", 
          "name": [
            "INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de La Sant\u00e9 & Traitement de l'Information M\u00e9dicale, Aix Marseille University, Marseille, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nishimwe", 
        "givenName": "Marie Lib\u00e9r\u00e9e", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Economic & Social Sciences, Health Systems & Medical Informatics", 
          "id": "https://www.grid.ac/institutes/grid.464064.4", 
          "name": [
            "INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de La Sant\u00e9 & Traitement de l'Information M\u00e9dicale, Aix Marseille University, Marseille, France.", 
            "ORS PACA, Observatoire R\u00e9gional de la Sant\u00e9 Provence-Alpes-C\u00f4te d'Azur, Marseille, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bousmah", 
        "givenName": "Marw\u00e2n-Al-Qays", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Economic & Social Sciences, Health Systems & Medical Informatics", 
          "id": "https://www.grid.ac/institutes/grid.464064.4", 
          "name": [
            "INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de La Sant\u00e9 & Traitement de l'Information M\u00e9dicale, Aix Marseille University, Marseille, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Janah", 
        "givenName": "Asmaa", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Saint-Antoine", 
          "id": "https://www.grid.ac/institutes/grid.412370.3", 
          "name": [
            "AP-HP, H\u00f4pital Saint-Antoine, Paris, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Girard", 
        "givenName": "Pierre-Marie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Bordeaux", 
          "id": "https://www.grid.ac/institutes/grid.42399.35", 
          "name": [
            "INSERM Bordeaux Population Health Research Center, UMR 1219, CIC1401-EC, University of Bordeaux, ISPED, 33000, Bordeaux, France.", 
            "CHU Bordeaux, Division of Public Health, 33000, Bordeaux, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ch\u00eane", 
        "givenName": "Genevi\u00e8ve", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Bordeaux", 
          "id": "https://www.grid.ac/institutes/grid.412041.2", 
          "name": [
            "INSERM Bordeaux Population Health Research Center, UMR 1219, CIC1401-EC, University of Bordeaux, ISPED, 33000, Bordeaux, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moinot", 
        "givenName": "Laetitia", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Economic & Social Sciences, Health Systems & Medical Informatics", 
          "id": "https://www.grid.ac/institutes/grid.464064.4", 
          "name": [
            "INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de La Sant\u00e9 & Traitement de l'Information M\u00e9dicale, Aix Marseille University, Marseille, France.", 
            "ORS PACA, Observatoire R\u00e9gional de la Sant\u00e9 Provence-Alpes-C\u00f4te d'Azur, Marseille, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sagaon-Teyssier", 
        "givenName": "Luis", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Saint-Antoine", 
          "id": "https://www.grid.ac/institutes/grid.412370.3", 
          "name": [
            "AP-HP, H\u00f4pital Saint-Antoine, Paris, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meynard", 
        "givenName": "Jean-Luc", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Economic & Social Sciences, Health Systems & Medical Informatics", 
          "id": "https://www.grid.ac/institutes/grid.464064.4", 
          "name": [
            "INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de La Sant\u00e9 & Traitement de l'Information M\u00e9dicale, Aix Marseille University, Marseille, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spire", 
        "givenName": "Bruno", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Economic & Social Sciences, Health Systems & Medical Informatics", 
          "id": "https://www.grid.ac/institutes/grid.464064.4", 
          "name": [
            "INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de La Sant\u00e9 & Traitement de l'Information M\u00e9dicale, Aix Marseille University, Marseille, France. sylvie.boyer@inserm.fr."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boyer", 
        "givenName": "Sylvie", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0149-2918(00)80088-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003773012"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1099-1050(200010)9:7<623::aid-hec539>3.0.co;2-v", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004589882"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.d1548", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007542476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0023726", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014207157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40273-016-0396-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017511779", 
          "https://doi.org/10.1007/s40273-016-0396-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qad.0b013e32834dce6e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028448275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qad.0b013e32834dce6e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028448275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13561-014-0015-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031841384", 
          "https://doi.org/10.1186/s13561-014-0015-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13561-014-0015-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031841384", 
          "https://doi.org/10.1186/s13561-014-0015-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ije/dyr164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035255426"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0167-6296(01)00086-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036510207"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s2352-3018(15)00176-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036638508"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1472-6963-6-52", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038300353", 
          "https://doi.org/10.1186/1472-6963-6-52"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkq327", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041534574"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkq327", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041534574"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11592220-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042630136", 
          "https://doi.org/10.2165/11592220-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/hiv.12348", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053661511"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/apc.2015.0199", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059229724"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1310/hct1306-308", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064986505"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1590/s1020-49892002000800017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068108131"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078964989", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079016287", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qad.0000000000001467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084196397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qad.0000000000001467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084196397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dky055", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100953511"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/cid/ciy382", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103997357"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-09", 
    "datePublishedReg": "2019-04-09", 
    "description": "BACKGROUND: Protease inhibitor monotherapy is a simplified treatment strategy for virally suppressed HIV-positive patients that has the potential for cost savings, as fewer drugs are used than with combination therapy. However, evidence for its economic value is limited.\nOBJECTIVES: We assessed the cost-effectiveness of lopinavir/ritonavir monotherapy followed by treatment intensification in case of viral load rebound versus combination antiretroviral therapy (cART) with efavirenz/emtricitabine/tenofovir in HIV-1 infected patients with viral suppression in the ANRS 140 DREAM trial.\nMETHODS: DREAM was conducted in 36 French Hospitals between 2009 and 2013. For each treatment strategy, we estimated the unadjusted and multivariate-adjusted mean costs (in \u20ac, year 2010 values) and quality-adjusted life-years (QALYs) per patient, as well as incremental costs and QALYs per patient. We then assessed uncertainty using the cost-effectiveness acceptability curve, scenario analyses and cost-effectiveness price-threshold (CEPT) analysis.\nRESULTS: In the base-case analysis considering 2009-2013 antiretroviral drug (ARV) prices, adjusted incremental costs and QALYs were - \u20ac3296 (95% confidence interval [CI] - 5202 to - 1391) and 0.006 (95% CI - 0.021 to 0.033), respectively, over 2\u00a0years, suggesting that monotherapy was cost-effective with a probability of 100% at various cost-effectiveness thresholds. In scenario analyses considering 2018 ARV prices, monotherapy remained cost-effective but with a lower probability (94% vs. 100% in the base-case analysis). The current price of cART would have to decrease by 34% to be cost-effective with a probability of 95%.\nCONCLUSION: Monotherapy appears to be cost-effective compared with cART for virologically suppressed HIV-positive patients in France. CEPT analysis is a useful tool to identify the preferred strategy to adopt given that ARV prices change rapidly.\nTRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT00946595.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s41669-019-0130-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1284515", 
        "issn": [
          "2509-4262", 
          "2509-4254"
        ], 
        "name": "PharmacoEconomics - Open", 
        "type": "Periodical"
      }
    ], 
    "name": "Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM).", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s41669-019-0130-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113328131"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101700780"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30968368"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s41669-019-0130-7", 
      "https://app.dimensions.ai/details/publication/pub.1113328131"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000375_0000000375/records_91441_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s41669-019-0130-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s41669-019-0130-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s41669-019-0130-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s41669-019-0130-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s41669-019-0130-7'


 

This table displays all metadata directly associated to this object as RDF triples.

197 TRIPLES      20 PREDICATES      46 URIs      16 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s41669-019-0130-7 schema:about anzsrc-for:14
2 anzsrc-for:1402
3 schema:author N1d1fe3e7427c4d9bb84d892c97239559
4 schema:citation sg:pub.10.1007/s40273-016-0396-x
5 sg:pub.10.1186/1472-6963-6-52
6 sg:pub.10.1186/s13561-014-0015-5
7 sg:pub.10.2165/11592220-000000000-00000
8 https://app.dimensions.ai/details/publication/pub.1078964989
9 https://app.dimensions.ai/details/publication/pub.1079016287
10 https://doi.org/10.1002/1099-1050(200010)9:7<623::aid-hec539>3.0.co;2-v
11 https://doi.org/10.1016/s0149-2918(00)80088-0
12 https://doi.org/10.1016/s0167-6296(01)00086-8
13 https://doi.org/10.1016/s2352-3018(15)00176-9
14 https://doi.org/10.1089/apc.2015.0199
15 https://doi.org/10.1093/cid/ciy382
16 https://doi.org/10.1093/ije/dyr164
17 https://doi.org/10.1093/jac/dkq327
18 https://doi.org/10.1093/jac/dky055
19 https://doi.org/10.1097/qad.0000000000001467
20 https://doi.org/10.1097/qad.0b013e32834dce6e
21 https://doi.org/10.1111/hiv.12348
22 https://doi.org/10.1136/bmj.d1548
23 https://doi.org/10.1310/hct1306-308
24 https://doi.org/10.1371/journal.pone.0023726
25 https://doi.org/10.1590/s1020-49892002000800017
26 schema:datePublished 2019-04-09
27 schema:datePublishedReg 2019-04-09
28 schema:description BACKGROUND: Protease inhibitor monotherapy is a simplified treatment strategy for virally suppressed HIV-positive patients that has the potential for cost savings, as fewer drugs are used than with combination therapy. However, evidence for its economic value is limited. OBJECTIVES: We assessed the cost-effectiveness of lopinavir/ritonavir monotherapy followed by treatment intensification in case of viral load rebound versus combination antiretroviral therapy (cART) with efavirenz/emtricitabine/tenofovir in HIV-1 infected patients with viral suppression in the ANRS 140 DREAM trial. METHODS: DREAM was conducted in 36 French Hospitals between 2009 and 2013. For each treatment strategy, we estimated the unadjusted and multivariate-adjusted mean costs (in €, year 2010 values) and quality-adjusted life-years (QALYs) per patient, as well as incremental costs and QALYs per patient. We then assessed uncertainty using the cost-effectiveness acceptability curve, scenario analyses and cost-effectiveness price-threshold (CEPT) analysis. RESULTS: In the base-case analysis considering 2009-2013 antiretroviral drug (ARV) prices, adjusted incremental costs and QALYs were - €3296 (95% confidence interval [CI] - 5202 to - 1391) and 0.006 (95% CI - 0.021 to 0.033), respectively, over 2 years, suggesting that monotherapy was cost-effective with a probability of 100% at various cost-effectiveness thresholds. In scenario analyses considering 2018 ARV prices, monotherapy remained cost-effective but with a lower probability (94% vs. 100% in the base-case analysis). The current price of cART would have to decrease by 34% to be cost-effective with a probability of 95%. CONCLUSION: Monotherapy appears to be cost-effective compared with cART for virologically suppressed HIV-positive patients in France. CEPT analysis is a useful tool to identify the preferred strategy to adopt given that ARV prices change rapidly. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT00946595.
29 schema:genre research_article
30 schema:inLanguage en
31 schema:isAccessibleForFree false
32 schema:isPartOf sg:journal.1284515
33 schema:name Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM).
34 schema:productId N5adf7f11fa794d7da0dd4f45fabed8f8
35 Na6bf59c1b6d34eeda8e6b49ced9a192d
36 Nabaa3ea95fcc4c0ca0aed2e9e69c262c
37 Nfd729ac582ac42c4b0d0517a860562c6
38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113328131
39 https://doi.org/10.1007/s41669-019-0130-7
40 schema:sdDatePublished 2019-04-15T09:01
41 schema:sdLicense https://scigraph.springernature.com/explorer/license/
42 schema:sdPublisher N160e8bd0e29c401aa88df236eacb921f
43 schema:url http://link.springer.com/10.1007/s41669-019-0130-7
44 sgo:license sg:explorer/license/
45 sgo:sdDataset articles
46 rdf:type schema:ScholarlyArticle
47 N0a7fa144cd6440be934ae41f27b2c451 rdf:first Nd2230daca87648a99b8caeffbf1a11ea
48 rdf:rest N7e01dc8402394b76a1fffa39634106a4
49 N160e8bd0e29c401aa88df236eacb921f schema:name Springer Nature - SN SciGraph project
50 rdf:type schema:Organization
51 N161276742a284fc284cb532edd2c8643 rdf:first N95b32e9a8bcd4de58641c4a432c33aef
52 rdf:rest N2dda3d70acc94a42be96436522cc162c
53 N1ac075ad64ec418f801ea209c4330ca0 schema:affiliation https://www.grid.ac/institutes/grid.464064.4
54 schema:familyName Janah
55 schema:givenName Asmaa
56 rdf:type schema:Person
57 N1d1fe3e7427c4d9bb84d892c97239559 rdf:first Ne384b74555b34c35a0cdf90f46fe9bc3
58 rdf:rest Nc4fe73bd9741413b9059c884f6aa2d6f
59 N1f8809b017d24d848f653f9fc30e78bc rdf:first N60727528193a46b5b6ac5c63eb6e74e1
60 rdf:rest N6fad13ede621437dadf20a1386771988
61 N2dda3d70acc94a42be96436522cc162c rdf:first N6bca2969699441dcbc6048cb6e4ce0ae
62 rdf:rest Naeeb28d4d87242da9006e9941d7aab65
63 N3610346bb8b4454185e7d4e29aa5d662 schema:affiliation https://www.grid.ac/institutes/grid.464064.4
64 schema:familyName Boyer
65 schema:givenName Sylvie
66 rdf:type schema:Person
67 N53490adc54464059bcaaf266cef3bbaf rdf:first Nccf9ddb9aa3948eabf6901d0ac028239
68 rdf:rest N0a7fa144cd6440be934ae41f27b2c451
69 N5adf7f11fa794d7da0dd4f45fabed8f8 schema:name doi
70 schema:value 10.1007/s41669-019-0130-7
71 rdf:type schema:PropertyValue
72 N60727528193a46b5b6ac5c63eb6e74e1 schema:affiliation https://www.grid.ac/institutes/grid.464064.4
73 schema:familyName Bousmah
74 schema:givenName Marwân-Al-Qays
75 rdf:type schema:Person
76 N6bca2969699441dcbc6048cb6e4ce0ae schema:affiliation https://www.grid.ac/institutes/grid.42399.35
77 schema:familyName Chêne
78 schema:givenName Geneviève
79 rdf:type schema:Person
80 N6db8d5735d314b9e97512a5a537e4609 schema:affiliation https://www.grid.ac/institutes/grid.464064.4
81 schema:familyName Sagaon-Teyssier
82 schema:givenName Luis
83 rdf:type schema:Person
84 N6fad13ede621437dadf20a1386771988 rdf:first N1ac075ad64ec418f801ea209c4330ca0
85 rdf:rest N161276742a284fc284cb532edd2c8643
86 N7e01dc8402394b76a1fffa39634106a4 rdf:first N3610346bb8b4454185e7d4e29aa5d662
87 rdf:rest rdf:nil
88 N95b32e9a8bcd4de58641c4a432c33aef schema:affiliation https://www.grid.ac/institutes/grid.412370.3
89 schema:familyName Girard
90 schema:givenName Pierre-Marie
91 rdf:type schema:Person
92 Na6bf59c1b6d34eeda8e6b49ced9a192d schema:name dimensions_id
93 schema:value pub.1113328131
94 rdf:type schema:PropertyValue
95 Nabaa3ea95fcc4c0ca0aed2e9e69c262c schema:name pubmed_id
96 schema:value 30968368
97 rdf:type schema:PropertyValue
98 Naeeb28d4d87242da9006e9941d7aab65 rdf:first Nc60908ffe76a4ef7adb19e77e6f6b80b
99 rdf:rest Nef28ac4dba62421386c86c7f71f2e6fa
100 Nc1bce0ad0ca242299f3879eee64aecd4 schema:affiliation https://www.grid.ac/institutes/grid.464064.4
101 schema:familyName Nishimwe
102 schema:givenName Marie Libérée
103 rdf:type schema:Person
104 Nc4fe73bd9741413b9059c884f6aa2d6f rdf:first Nc1bce0ad0ca242299f3879eee64aecd4
105 rdf:rest N1f8809b017d24d848f653f9fc30e78bc
106 Nc60908ffe76a4ef7adb19e77e6f6b80b schema:affiliation https://www.grid.ac/institutes/grid.412041.2
107 schema:familyName Moinot
108 schema:givenName Laetitia
109 rdf:type schema:Person
110 Nccf9ddb9aa3948eabf6901d0ac028239 schema:affiliation https://www.grid.ac/institutes/grid.412370.3
111 schema:familyName Meynard
112 schema:givenName Jean-Luc
113 rdf:type schema:Person
114 Nd2230daca87648a99b8caeffbf1a11ea schema:affiliation https://www.grid.ac/institutes/grid.464064.4
115 schema:familyName Spire
116 schema:givenName Bruno
117 rdf:type schema:Person
118 Ne384b74555b34c35a0cdf90f46fe9bc3 schema:affiliation https://www.grid.ac/institutes/grid.464064.4
119 schema:familyName Garay
120 schema:givenName Osvaldo Ulises
121 rdf:type schema:Person
122 Nef28ac4dba62421386c86c7f71f2e6fa rdf:first N6db8d5735d314b9e97512a5a537e4609
123 rdf:rest N53490adc54464059bcaaf266cef3bbaf
124 Nfd729ac582ac42c4b0d0517a860562c6 schema:name nlm_unique_id
125 schema:value 101700780
126 rdf:type schema:PropertyValue
127 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
128 schema:name Economics
129 rdf:type schema:DefinedTerm
130 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
131 schema:name Applied Economics
132 rdf:type schema:DefinedTerm
133 sg:journal.1284515 schema:issn 2509-4254
134 2509-4262
135 schema:name PharmacoEconomics - Open
136 rdf:type schema:Periodical
137 sg:pub.10.1007/s40273-016-0396-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1017511779
138 https://doi.org/10.1007/s40273-016-0396-x
139 rdf:type schema:CreativeWork
140 sg:pub.10.1186/1472-6963-6-52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038300353
141 https://doi.org/10.1186/1472-6963-6-52
142 rdf:type schema:CreativeWork
143 sg:pub.10.1186/s13561-014-0015-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031841384
144 https://doi.org/10.1186/s13561-014-0015-5
145 rdf:type schema:CreativeWork
146 sg:pub.10.2165/11592220-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042630136
147 https://doi.org/10.2165/11592220-000000000-00000
148 rdf:type schema:CreativeWork
149 https://app.dimensions.ai/details/publication/pub.1078964989 schema:CreativeWork
150 https://app.dimensions.ai/details/publication/pub.1079016287 schema:CreativeWork
151 https://doi.org/10.1002/1099-1050(200010)9:7<623::aid-hec539>3.0.co;2-v schema:sameAs https://app.dimensions.ai/details/publication/pub.1004589882
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1016/s0149-2918(00)80088-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003773012
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1016/s0167-6296(01)00086-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036510207
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1016/s2352-3018(15)00176-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036638508
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1089/apc.2015.0199 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059229724
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1093/cid/ciy382 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103997357
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1093/ije/dyr164 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035255426
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1093/jac/dkq327 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041534574
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1093/jac/dky055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100953511
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1097/qad.0000000000001467 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084196397
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1097/qad.0b013e32834dce6e schema:sameAs https://app.dimensions.ai/details/publication/pub.1028448275
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1111/hiv.12348 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053661511
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1136/bmj.d1548 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007542476
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1310/hct1306-308 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064986505
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1371/journal.pone.0023726 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014207157
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1590/s1020-49892002000800017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068108131
182 rdf:type schema:CreativeWork
183 https://www.grid.ac/institutes/grid.412041.2 schema:alternateName University of Bordeaux
184 schema:name INSERM Bordeaux Population Health Research Center, UMR 1219, CIC1401-EC, University of Bordeaux, ISPED, 33000, Bordeaux, France.
185 rdf:type schema:Organization
186 https://www.grid.ac/institutes/grid.412370.3 schema:alternateName Hôpital Saint-Antoine
187 schema:name AP-HP, Hôpital Saint-Antoine, Paris, France.
188 rdf:type schema:Organization
189 https://www.grid.ac/institutes/grid.42399.35 schema:alternateName Centre Hospitalier Universitaire de Bordeaux
190 schema:name CHU Bordeaux, Division of Public Health, 33000, Bordeaux, France.
191 INSERM Bordeaux Population Health Research Center, UMR 1219, CIC1401-EC, University of Bordeaux, ISPED, 33000, Bordeaux, France.
192 rdf:type schema:Organization
193 https://www.grid.ac/institutes/grid.464064.4 schema:alternateName Economic & Social Sciences, Health Systems & Medical Informatics
194 schema:name INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de La Santé & Traitement de l'Information Médicale, Aix Marseille University, Marseille, France.
195 INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de La Santé & Traitement de l'Information Médicale, Aix Marseille University, Marseille, France. sylvie.boyer@inserm.fr.
196 ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France.
197 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...